Enzyl Capsule

Product Overview

About Enzyl

Enzyl is a medication containing the active ingredient Enzalutamide, classified as Androgen Receptor Inhibitor. Enzalutamide, sold under the brand name Xtandi, is a nonsteroidal antiandrogen (NSAA) medication which is used in the treatment of prostate cancer.

Key Benefits & Uses

• Used for: 1 INDICATIONS AND USAGE XTANDI ® is indicated for the treatment of patients with: • castration-resistant prostate cancer (CRPC) • metastatic.
• Use only as directed on the product label or by a healthcare professional.
• Follow the authorised product information for dosing and duration of use.

Active Ingredient & Action

Enzalutamide, the active ingredient in Enzyl, belongs to the Androgen Receptor Inhibitor class. 1 INDICATIONS AND USAGE XTANDI ® is indicated for the treatment of patients with: • castration-resistant prostate cancer (CRPC) • metastatic castration-sensitive prostate cancer (mCSPC) • non‑metastatic castration‑sensitive prostate cancer (nmCSPC) with biochemical recurrence at high risk for metastasis (high-risk. Inactive ingredients: not listed in source data.

Important Notes

Always read and follow the label instructions carefully before taking Enzyl. If you have any underlying medical conditions, are taking other medicines, or are pregnant or breastfeeding, consult a doctor or pharmacist before use. Do not exceed the recommended dose on the package and do not use Enzyl for extended periods without medical advice.